Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial.

Scott IU, VanVeldhuisen PC, Barton F, Oden NL, Ip MS, Blodi BA, Worrall M, Fish GE; Study of Comparative Treatments for Retinal Vein Occlusion 2 Investigator Group.

JAMA Ophthalmol. 2019 Jun 6. doi: 10.1001/jamaophthalmol.2019.1519. [Epub ahead of print]

PMID:
31169862
2.

Intraoperative aberrometry versus preoperative biometry for intraocular lens power selection in short eyes.

Sudhakar S, Hill DC, King TS, Scott IU, Mishra G, Ernst BB, Pantanelli SM.

J Cataract Refract Surg. 2019 Jun;45(6):719-724. doi: 10.1016/j.jcrs.2018.12.016. Epub 2019 Mar 8.

PMID:
30853316
3.

Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.

Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group.

JAMA Ophthalmol. 2018 Dec 27. doi: 10.1001/jamaophthalmol.2018.6111. [Epub ahead of print]

PMID:
30589922
4.

Virtual eye surgery training in ophthalmic graduate medical education.

Paul SK, Clark MA, Scott IU, Greenberg PB.

Can J Ophthalmol. 2018 Dec;53(6):e218-e220. doi: 10.1016/j.jcjo.2018.03.018. Epub 2018 May 18. No abstract available.

PMID:
30502995
5.

Reducing the Disclosure Effect in the Vitreoretinal Fellowship Match.

Greenberg PB, Scott IU, Chen AJ.

JAMA Ophthalmol. 2019 Jan 1;137(1):119-120. doi: 10.1001/jamaophthalmol.2018.4990. No abstract available.

PMID:
30347022
6.

Low vision services: a practical guide for the clinician.

Shah P, Schwartz SG, Gartner S, Scott IU, Flynn HW Jr.

Ther Adv Ophthalmol. 2018 Jun 11;10:2515841418776264. doi: 10.1177/2515841418776264. eCollection 2018 Jan-Dec.

7.

Optical Coherence Tomography Angiography.

Schwartz SG, Flynn HW Jr, Grzybowski A, Pathengay A, Scott IU.

Case Rep Ophthalmol Med. 2018 Jun 6;2018:7140164. doi: 10.1155/2018/7140164. eCollection 2018. No abstract available.

8.

Resident Wellness in US Ophthalmic Graduate Medical Education: The Resident Perspective.

Tran EM, Scott IU, Clark MA, Greenberg PB.

JAMA Ophthalmol. 2018 Jun 1;136(6):695-701. doi: 10.1001/jamaophthalmol.2018.1383.

9.

LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS.

Peterson JS, Rockwell K Jr, Scott IU, Ip MS, VanVeldhuisen PC, Blodi BA; SCORE2 Investigator Group.

Retina. 2018 May 9. doi: 10.1097/IAE.0000000000002212. [Epub ahead of print]

PMID:
29746405
10.

Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Altaweel M, Berinstein DM; SCORE2 Investigator Group.

JAMA Ophthalmol. 2018 Apr 1;136(4):337-345. doi: 10.1001/jamaophthalmol.2017.6843.

11.

Comparative efficacy of two different topical povidone-iodine 5% regimens in reducing conjunctival bacterial flora: A randomized parallel double-masked clinical trial.

Barroso LF, Cazella SP, Nepomuceno AB, Toscano L, Castilho LÂS, Furlan EMR, Messias A, Scott IU, Jorge R.

PLoS One. 2017 Dec 19;12(12):e0189206. doi: 10.1371/journal.pone.0189206. eCollection 2017.

12.

SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.

Scott IU, Figueroa MJ, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE2 Investigator Group.

Am J Ophthalmol. 2017 Dec;184:147-156. doi: 10.1016/j.ajo.2017.10.008. Epub 2017 Oct 23.

13.

Choroidal neovascularization silent on optical coherence tomography: report of two cases.

Borges FP, Siqueira RC, Scott IU, Cardillo JA, Jorge R.

Arq Bras Oftalmol. 2017 Jul-Aug;80(4):263-265. doi: 10.5935/0004-2749.20170064.

14.

Evolving Role of Regional Depot Corticosteroids in Management of Diabetic Macular Edema.

Kim SJ, Scott IU.

Retina. 2017 Dec;37(12):2201-2207. doi: 10.1097/IAE.0000000000001826. No abstract available.

PMID:
28837536
15.

Assessing and Promoting the Wellness of United States Ophthalmology Residents: A Survey of Program Directors.

Tran EM, Scott IU, Clark MA, Greenberg PB.

J Surg Educ. 2018 Jan - Feb;75(1):95-103. doi: 10.1016/j.jsurg.2017.06.012. Epub 2017 Jul 8.

PMID:
28693982
16.

Practice Patterns Among Eye Care Providers at US Teaching Hospitals With Regard to Assessing and Educating Patients About Smoking.

Landis ZC, Rolius R, Scott IU.

Am J Ophthalmol. 2017 Aug;180:86-90. doi: 10.1016/j.ajo.2017.05.023. Epub 2017 Jun 1.

PMID:
28579064
17.

Foveal thickness reduction after anti-vascular endothelial growth factor treatment in chronic diabetic macular edema.

Willmann G, Nepomuceno AB, Messias K, Barroso L, Scott IU, Messias A, Jorge R.

Int J Ophthalmol. 2017 May 18;10(5):760-764. doi: 10.18240/ijo.2017.05.17. eCollection 2017.

18.

Intraoperative aberrometry versus preoperative biometry for intraocular lens power selection in axial myopia.

Hill DC, Sudhakar S, Hill CS, King TS, Scott IU, Ernst BB, Pantanelli SM.

J Cataract Refract Surg. 2017 Apr;43(4):505-510. doi: 10.1016/j.jcrs.2017.01.014.

PMID:
28532936
19.

Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J; SCORE2 Investigator Group.

JAMA. 2017 May 23;317(20):2072-2087. doi: 10.1001/jama.2017.4568.

20.

Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, King J, Antoszyk AN, Peters MA, Tolentino M; SCORE2 Investigator Group.

JAMA Ophthalmol. 2017 Jun 1;135(6):639-649. doi: 10.1001/jamaophthalmol.2017.1141.

21.

Trends in cataract surgery training curricula.

Lotfipour M, Rolius R, Lehman EB, Pantanelli SM, Scott IU.

J Cataract Refract Surg. 2017 Jan;43(1):49-53. doi: 10.1016/j.jcrs.2016.10.020.

PMID:
28317677
22.

SCORE2 Report 2: Study Design and Baseline Characteristics.

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M, Dugel PU; SCORE2 Investigator Group.

Ophthalmology. 2017 Feb;124(2):245-256. doi: 10.1016/j.ophtha.2016.09.038. Epub 2016 Nov 15.

23.

Update on corticosteroids for diabetic macular edema.

Schwartz SG, Scott IU, Stewart MW, Flynn HW Jr.

Clin Ophthalmol. 2016 Sep 8;10:1723-30. doi: 10.2147/OPTH.S115546. eCollection 2016. Review.

24.

SAFETY AND FEASIBILITY OF A NOVEL 25-GAUGE BIODEGRADABLE IMPLANT OF DEXAMETHASONE FOR TREATMENT OF MACULAR EDEMA ASSOCIATED WITH RETINAL VEIN OCCLUSION: A PHASE I CLINICAL TRIAL.

Cunha RB, Siqueira RC, Messias A, Scott IU, Fialho SL, Cunha-Junior ADS, Jorge R.

Retin Cases Brief Rep. 2018 Winter;12(1):50-58. doi: 10.1097/ICB.0000000000000413.

PMID:
27632583
25.

Cataract Surgery in Hospice Patients: Pros, Cons, and Cost-Effectiveness.

Nunn JG, Shreve S, Scott IU, Pantanelli SM.

J Palliat Med. 2016 Dec;19(12):1245-1246. Epub 2016 Sep 1. No abstract available.

PMID:
27585302
26.

SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion.

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M; SCORE2 Investigator Group.

Am J Ophthalmol. 2016 Oct;170:25-31. doi: 10.1016/j.ajo.2016.07.011. Epub 2016 Jul 19.

27.

Reply.

Sorenson R, Scott IU, Tucker SH, Chinchilli VM, Papachristou GC.

J Cataract Refract Surg. 2016 Jun;42(6):946. doi: 10.1016/j.jcrs.2016.04.018. No abstract available.

PMID:
27373408
28.

Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects.

Stewart MW, Flynn HW Jr, Schwartz SG, Scott IU.

Expert Opin Drug Deliv. 2016 Sep;13(9):1277-87. doi: 10.1080/17425247.2016.1198771. Epub 2016 Jun 22. Review.

PMID:
27293138
29.

Practice patterns of cataract surgeons at academic medical centers for the management of inadequate capsule support for intracapsular or sulcus intraocular lens placement during cataract surgery.

Sorenson R, Scott IU, Tucker SH, Chinchilli VM, Papachristou GC.

J Cataract Refract Surg. 2016 Feb;42(2):239-45. doi: 10.1016/j.jcrs.2015.09.022.

PMID:
27026448
30.

Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15.

Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group.

JAMA Ophthalmol. 2015 Sep;133(9):1022-9. doi: 10.1001/jamaophthalmol.2015.1823.

PMID:
26086920
31.

Ocular nutritional supplements: are their ingredients and manufacturers' claims evidence-based?

Yong JJ, Scott IU, Greenberg PB.

Ophthalmology. 2015 Mar;122(3):595-9. doi: 10.1016/j.ophtha.2014.09.039. Epub 2014 Nov 20.

PMID:
25458196
32.

Accidental subretinal brilliant blue G migration during internal limiting membrane peeling surgery.

Almeida FP, De Lucca AC, Scott IU, Jorge R, Messias A.

JAMA Ophthalmol. 2015 Jan;133(1):85-8. doi: 10.1001/jamaophthalmol.2014.3869.

PMID:
25321324
33.

Emerging drugs for diabetic macular edema.

Schwartz SG, Flynn HW Jr, Scott IU.

Expert Opin Emerg Drugs. 2014 Sep;19(3):397-405. doi: 10.1517/14728214.2014.938048. Epub 2014 Aug 21. Review.

PMID:
25141904
34.

Neuroprotective effects of intravitreal triamcinolone acetonide and dexamethasone implant in rabbit retinas after pars plana vitrectomy and silicone oil injection.

Siqueira RC, Dos Santos WF, Scott IU, Messias A, Rosa MN, Fernandes Cunha GM, da Silva Cunha A Jr, Jorge R.

Retina. 2015 Feb;35(2):364-70. doi: 10.1097/IAE.0000000000000284.

PMID:
25111686
35.

Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in mild to moderate nonproliferative diabetic retinopathy: a randomized proof-of-concept clinical trial.

Scott IU, Jackson GR, Quillen DA, Klein R, Liao J, Gardner TW.

JAMA Ophthalmol. 2014 Sep;132(9):1137-42. doi: 10.1001/jamaophthalmol.2014.1422.

PMID:
24969516
36.

Improvement of ischaemic macular oedema after intravitreal injection of autologous bone marrow-derived haematopoietic stem cells.

Siqueira RC, Messias A, Gurgel VP, Simões BP, Scott IU, Jorge R.

Acta Ophthalmol. 2015 Mar;93(2):e174-6. doi: 10.1111/aos.12473. Epub 2014 Jun 22. No abstract available.

37.

Author response: additional considerations in the utility of dark adaptometry for the diagnosis of age-related macular degeneration.

Jackson GR, Scott IU, Kim IK, Quillen DA, Iannaccone A, Edwards JG.

Invest Ophthalmol Vis Sci. 2014 May 19;55(5):3149. doi: 10.1167/iovs.14-14569. No abstract available.

PMID:
24840311
38.

Twelve-month natural history of dark adaptation in patients with AMD.

Jackson GR, Clark ME, Scott IU, Walter LE, Quillen DA, Brigell MG.

Optom Vis Sci. 2014 Aug;91(8):925-31. doi: 10.1097/OPX.0000000000000247.

PMID:
24705482
39.

Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.

Fileta JB, Scott IU, Flynn HW Jr.

Ophthalmic Surg Lasers Imaging Retina. 2014 Mar-Apr;45(2):143-9. doi: 10.3928/23258160-20140306-08.

PMID:
24635156
40.
41.

Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration.

Jackson GR, Scott IU, Kim IK, Quillen DA, Iannaccone A, Edwards JG.

Invest Ophthalmol Vis Sci. 2014 Mar 10;55(3):1427-31. doi: 10.1167/iovs.13-13745.

42.

Povidone-iodine for endophthalmitis prophylaxis.

Ahmed Y, Scott IU, Pathengay A, Bawdekar A, Flynn HW Jr.

Am J Ophthalmol. 2014 Mar;157(3):503-4. doi: 10.1016/j.ajo.2013.12.001. No abstract available.

PMID:
24528933
43.

Mitomycin C versus 5-fluorouracil as an adjunctive treatment for trabeculectomy: a meta-analysis of randomized clinical trials.

De Fendi LI, Arruda GV, Scott IU, Paula JS.

Clin Exp Ophthalmol. 2013 Nov;41(8):798-806. Review.

PMID:
24308066
44.

Intravitreal Corticosteroids in the Management of Diabetic Macular Edema.

Schwartz SG, Flynn HW Jr, Scott IU.

Curr Ophthalmol Rep. 2013 Sep;1(3). doi: 10.1007/s40135-013-0015-3.

45.

Drug delivery techniques for treating age-related macular degeneration.

Schwartz SG, Scott IU, Flynn HW Jr, Stewart MW.

Expert Opin Drug Deliv. 2014 Jan;11(1):61-8. doi: 10.1517/17425247.2013.859135. Epub 2013 Nov 13. Review.

PMID:
24219407
46.

Association between systemic anticoagulation and rate of intraocular hemorrhage following intravitreal anti-VEGF therapy for age-related macular degeneration.

Olson JM, Scott IU, Kerchner DL, Kunselman AR.

Ophthalmic Surg Lasers Imaging Retina. 2013 Sep-Oct;44(5):455-9. doi: 10.3928/23258160-20130909-06.

PMID:
24044707
47.

Ophthalmic resident education on preventable surgical errors.

Chen AJ, Chan JJ, Scott IU, Greenberg PB.

JAMA Ophthalmol. 2013 Sep;131(9):1238-40. doi: 10.1001/jamaophthalmol.2013.1691. No abstract available.

PMID:
24030338
48.

Twenty-four-hour intraocular pressure monitoring: it's about time.

Aref AA, Scott IU.

JAMA Ophthalmol. 2013 Nov;131(11):1403-4. doi: 10.1001/jamaophthalmol.2013.4700. No abstract available.

PMID:
24030162
49.

What is the optimal timing for rhegmatogenous retinal detachment repair?

Wykoff CC, Flynn HW Jr, Scott IU.

JAMA Ophthalmol. 2013 Nov;131(11):1399-400. doi: 10.1001/jamaophthalmol.2013.4505. No abstract available.

PMID:
24008508
50.

Is the use of topical antibiotics for intravitreal injections the standard of care or are we better off without antibiotics?

Chen RW, Rachitskaya A, Scott IU, Flynn HW Jr.

JAMA Ophthalmol. 2013 Jul;131(7):840-2. doi: 10.1001/jamaophthalmol.2013.2524. No abstract available.

PMID:
23846201

Supplemental Content

Loading ...
Support Center